Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 11, 2023

Efficacy and Safety of 4-Year Ofatumumab Treatment in Patients With Relapsing MS

Multiple Sclerosis (Houndmills, Basingstoke, England)


Additional Info

Disclosure statements are available on the authors' profiles:

Multiple Sclerosis (Houndmills, Basingstoke, England)
Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension
Mult. Scler. 2023 Sep 11;[EPub Ahead of Print], SL Hauser, R Zielman, A Das Gupta, J Xi, D Stoneman, G Karlsson, D Robertson, JA Cohen, L Kappos

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading